Classifying Epilepsy Pragmatically: Past, Present, and Future

Nathan A. Shlobin\textsuperscript{a}, Gagandeep Singh\textsuperscript{b,c}, Charles R. Newton\textsuperscript{d}, Josemir W. Sander \textsuperscript{c,f}

\textsuperscript{a} Department of Neurological Surgery, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA

\textsuperscript{b} Department of Neurology, Dayanand Medical College, Ludhiana, India

\textsuperscript{c} NIHR University College London Hospitals Biomedical Research Centre, UCL Queen Square Institute of Neurology, Queen Square, London WC1N 3BG & Chalfont Centre for Epilepsy, Chalfont St Peter SL9 0RJ, UK

\textsuperscript{d} Department of Psychiatry, University of Oxford, Oxford, UK

\textsuperscript{e} Kenya Medical Research Institute, Kilifi, Kenya

\textsuperscript{f} Stichting Epilepsie InstelClingen Nederland (SEIN), Heemstede, The Netherlands

Corresponding author:
Prof Ley Sander, MD PhD FRCP FEAN
Box 29, UCL Queen Square Institute of Neurology
London WC1N 3BG, United Kingdom
E-mail: l.sander@ucl.ac.uk
Classifying Epilepsy Pragmatically: Past, Present, and Future

Abstract:
The classification of epilepsy is important for people with epilepsy and their families, health-care providers, physicians and researchers. The International League Against Epilepsy proposed updated seizure and epilepsy classifications in 2017, while another four-dimensional epilepsy classification was updated in 2019. An Integrated Epilepsy Classification system was proposed in 2020. Existing classifications, however, lack consideration of important pragmatic factors relevant to the day-to-day life of people with epilepsy and stakeholders. Comorbidities in brain development, genetic causes and environmental triggers of epilepsy are increasingly not reflected in current classifications. Demographics of epilepsy have changed over time while existing classification schemes exhibit caveats. A pragmatic classification scheme should incorporate these factors to provide a nuanced classification. Validation across disparate contexts will ensure widespread applicability and ease of use. A team-based approach will simplify communication between health-care personnel. An individual-centred perspective will empower people with epilepsy. Together, incorporating these elements into a modern but pragmatic classification scheme will ensure optimal care for people with epilepsy by streamlining communication between its myriad users. Technological advancements such as 7T MRI, next-generation sequencing, and artificial intelligence are likely to affect future classification efforts.

Keywords: integrated epilepsy classification, 2017 ILAE classification, four-dimensional epilepsy classification, epilepsy

Declarations of interest: none in relation to this work. This work did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Introduction

Epilepsy classification is important for people with epilepsy, caregivers, health-care personnel, researchers, policymakers, and insurers [1, 2]. Classification allows people with epilepsy to identify with a well-defined condition, empowering them and providing a direction to engage with others. Classification schemes also clarify communication, enhancing care and augmenting education and training [1-3].

The first classification of seizures and epilepsies was conceived in 1964 and popularised in the 1970’s [2, 4, 5]. Classifications have been published under the aegis of the International league Against Epilepsy (ILAE) with the most recent updates in 2017 [2, 6, 7]. In 2001, a multi-dimensional classification scheme with five axes [8] and in 2012, a four-dimensional classification scheme was proposed [9, 10]. An Integrated Epilepsy Classification (IEC) scheme based on commonalities between the ILAE and four-dimensional classification schemes was proposed [11]. Classification continues to evolve while enduring lively debates and having been criticised for its focus on detail and at the same time, lack of inclusiveness and pragmatism [12].

Given the importance of classification, it is crucial to consider the need for further refinement and adaptability. We revisit past and present milestones in epilepsy classification, review past and existing classifications, propose future considerations, and examine rising technologies’ influence. This review provides consideration of previously undervalued factors influencing the debate on the ever-evolving epilepsy classification.

Past and Current Classifications

ILAE published in 1981 its first seizure classification after the development of video-EEG monitoring (Table 1) [13, 14]. Seizures were divided into partial and generalised according to onset. The 1985 epilepsies classification scheme was based on semiology with age dependency and etiology in addition to EEG features [14, 15]. ILAE revised its proposal in 1989 with categories including localisation-related epilepsies and syndromes, generalised epilepsies and syndromes, undetermined syndromes and special syndromes [14, 16].

Contemporaneously, an ILAE expert group also proposed an epidemiologic classification of epilepsies [17]. A diagnostic scheme proposed in 2001 involved five axes mirroring those of the DSM IV: ictal phenomenology, seizure type, syndrome, etiology, and impairment [8, 14]. The 2006 update of this scheme further delineated self-limited epilepsy syndromes [1, 14, 18]. Another proposal (2010) incorporated the concept of brain networks between subcortical and cortical structures and between cortical areas [14, 19]. Non-mutually exclusive etiological classifications such as genetic, structural, metabolic, and unknown were created [14, 19]. ILAE Commissions generated new classifications for seizures and epilepsies in 2017 (ILAE-EC) involving seizure type, epilepsy types, and etiologies [6, 7, 14, 20].

A group of experts proposed a classification entirely based on seizure semiology in 1998 [21-23]. They offered a five-dimensional individual-oriented classification scheme consisting epileptogenic zone location, seizure semiology, etiology, seizure frequency, and related conditions in 2005 [24]. A four-dimensional classification (4D-EC) system consisting of semiology of the seizures, epileptogenic zone location, aetiology, and associated comorbidities was proposed in 2012 [9, 10]. The updated four-dimensional classification scheme (4D-CS) comprises a sequential approach to categorising non-specific paroxysmal events [10]. The current ILAE classification and 4D-CS were merged into the IEC after consideration of
similarities between the two [11]. The IEC contains five subcategories: header, seizure type, epilepsy type, etiology, and comorbidities and relevant individual preferences [11].

The Past and Present Classifications

The intense debate on epilepsy classification is reassuring. Numerous proposals and refutations notwithstanding, the discussions bear out experts' engagement in the evolution of classification. Limitations, however, have arisen at each step. Some stem from the semantics, syntax and semiotics of seizures. For instance, the term dialeptic seizures has been used in the past to emphasise the phenomenon of behavioral arrest observed in absence seizures as well as mesial temporal seizures [25]. The term, dyscognitive seizures has also been used with diverse connotations by experts in the past, only to be removed in a later version of the classification [6, 7, 14, 20]. Descriptive terminology for mesial temporal seizures has evolved from complex partial seizures to dialeptic seizures, dyscognitive seizures, and focal seizures with or without impaired awareness [6]. The variety of expressions can be confusing to beginners and prove challenging for the experienced to relearn [25, 26]. To the credit of the creators, it is now accepted that any classification should be flexible to meet the needs of different users. There is also a perceived need to explore beyond the boundaries of current classifications to encompass horizons yet not covered.

Caveats in Classifications

Mutually exclusive etiological categories lead to confusion. For example, GLUT1 transporter deficiency may be denoted as genetic or metabolic [11], while neurocysticercosis may be classified as infective or structural. These ambiguities could be addressed by specifying etiological conditions precisely [11]. The classification of a specific condition may, however, have implications for the estimation of the burden of disease. Additionally, classifications have removed anatomical origins due to the imperfect relationship between location and semiology and the electro-clinical similarity between seizures arising from different lobes [1]. The character of seizures, however, bear a relationship to a lobe [27, 28]. The ILAE, 4D-EC, and IEC classifications also include syndromes with differing importance [6, 7, 10, 11]. Several population and facility-based studies have examined the yield of the syndromic classification. In these studies (Table 2), syndromes were unambiguously assigned in 4-97% of cases [29-35]. The variation represents the differences between samples assessed, methodologies used and experts' experience [36-38].

Comorbidities

People with epilepsy are up to eight times more likely to have conditions such as depression, anxiety, migraine, heart disease, peptic ulcers, and arthritis relative to the general population [39], and more likely to have other neuropsychiatric disorders, pain disorders, autoimmune diseases and asthma [40, 41]. The presence of comorbidities, however, must be assessed across different populations to gain acceptance [41, 42]. There seems to be a biological basis for the association of epilepsy with psychosomatic comorbidities [43-47]. Similarly, existing methods of quantifying comorbidities such as the Charlson Comorbidity Index
and Elixhauser Comorbidity Index are generally unsuitable for epilepsy [42]. An epilepsy-specific risk adjustment index may be necessary to account for comorbidities properly [42].

Inclusion of comorbidities into classification should be expanded. The 4D-CS and IEC included comorbidities [9-11], but they are not commonly incorporated into classifications. The occurrence and treatment of comorbidities influences the expression, treatment, and outcome, and vice-versa. A systematic classification of comorbidities should enumerate known comorbidities and suit the differing needs of the treatment providers of epilepsy and the comorbidities. Uniform documentation of associated comorbidities diagnoses will permit identification of appropriate treatments; increase consideration of the impact of comorbidities in epilepsy presentation and its treatment; and improve communication between different specialists.

Changes in the Demography of Epilepsy

While current classifications presume a static nature to populations, epilepsy demography has changed. An appropriate representation of these trends may provide a clearer categorisation of individuals with epilepsy.

First, temporal trends are important to examine. Epilepsy incidence is high in the first year of life, perhaps due to the high proportion of symptomatic cases presenting early in life [48]. Many of these children have epileptic encephalopathies, often with psychomotor arrest that predisposes developmental slowing and seizures later in life [48]. Other children have generalised or focal seizures of the neonatal or infantile period [48]. Medical technology has also contributed to the high first-year incidence as premature children and children with congenital anomalies or severe early life insults survive longer with a higher likelihood of developing epilepsy. Incidence declines by the end of the first decade [49, 50]. Decreased exposure to teratogens including some antiseizure medications (ASMs) and environmental risk factors may have enhanced the decrease [51, 52]. The incidence increases in the elderly due to cerebrovascular diseases, neurodegenerative disorders, intracerebral tumors, and traumatic brain injury [53-55], although standardisation account for this [54-56]. Second, consideration of changes in etiology of epilepsy is required. The concept of etiology of epilepsy has changed over time as conceptual models of causality in epilepsy continue to be developed and risk factors continue to be elucidated [57]. Third, the state of epilepsy is relevant. Whether a patient has active epilepsy or epilepsy in remission, controlled or uncontrolled epilepsy, and drug-resistant epilepsy influences the prognosis [58-60]. An adequate epilepsy classification must capture these distinctions to add relevance to clinical practice.

Incorporating the changing demographics of epilepsy will improve communication between specialists, allowing for the greater utility of classification schemes via an emphasis on most affected groups.

Brain Age

Brain development stages denoted as “brain age”, measured often as brain-predicted age difference (PAD) [61, 62], is probably more relevant than chronological age to epilepsy diagnosis and classification, influencing susceptibility to, presentation, and consequences of seizures. The onset or offset of seizures marks a turning point in brain development, demonstrated by regression of speech with seizure onset in Kleffner-Landau syndrome or
resumption of brain maturation with successful seizure control in West syndrome [63, 64]. In epileptic encephalopathies, brain maturation arrests at a given time point and might also regress. Therefore, consideration of how brain age or development is reflected in classification is important.

Developing, aging, or degenerating brains are highly susceptible to seizures [65, 66]. Brain maturation likely influences seizure semiology. Seizures are featureless, denoted as “hypomotor”, during infancy, plausibly reflecting limited neuronal connectivity, while automatisms and hypermotor seizures occur in older children with presumably mature brains [67]. Lateralizing signs increase with age in people with temporal epilepsy [68]. Epileptic spasms typically occur during infancy, while absence seizures, myoclonic-astatic, and generalised tonic-clonic seizures occur in later childhood [69, 70]. Lastly, there is evidence for an interaction between age and pharmacoresistance to ASMs, adversely impacting cognitive development and function in children with epilepsy. Cognitive impairments associated with uncontrolled seizures are particularly severe during infancy and decrease thereafter [71, 72]. Individuals with onset of temporal epilepsy in childhood exhibit greater reduction of brain tissue volumes, namely white matter in extratemporal regions, and more marked memory deficits [73].

While the quest for robust markers for brain age continues, it is conceivable that applications of artificial intelligence and machine learning will yield important insights to admit brain age to epilepsy classifications in the future.

**Genetic Etiologies**

Current classification paradigms incorporate genetic etiologies, but there exists little description of the specific genetic characteristics associated with the diagnosis. Polygenic theory suggests that an accumulation of single nucleotide polymorphisms associated with epilepsy may explain the propensity of certain individuals to develop epilepsy [74]. Conversely, pathogenic variants lead to epilepsy development through several mechanisms. Discovery of genes contributing to epilepsy is rapidly growing. Myriad single gene disorders have been implicated in epilepsy (Table 3) [47, 75, 76]. Common mechanisms include voltage-gated channelopathies [77-80], ligand-gated channelopathies [78, 79, 81-85], neurotransmitter release machinery [78, 86, 87], and structural alterations (Table 4) [78, 88]. Delineation of genetic attributes promotes research to elucidate the natural history of the condition, leads to the development of precision medications, guides treatment paradigms, facilitates preventative measures, and helps individuals with a genetic disorder connect with each other.

As genetic links for epilepsy are increasingly uncovered, conceptualising classification in terms of genetic causation becomes indispensable. Investigations such as chromosomal microarrays, whole genome and whole exome sequencing, and gene panels are now increasingly available. These investigations secure a genetic diagnosis and aid in the syndromic and etiological classification despite the cost and access issues. Specific syndromes benefit from contemporary genetic testing. These include epilepsies developing before the age of 2, especially epileptic encephalopathies, suspected and imaging-confirmed brain malformations, and certain inborn errors of metabolism and selected syndromes such as West Syndrome and Dravet Syndrome [89-92]. Undoubtedly, the elucidation of a genetic diagnosis is likely to influence classification elements and systems in the future.
Environmental Triggers

Environmental factors might contribute to susceptibility to and development of epilepsy. Febrile infections herald fever-related syndromes [93, 94]. Malnutrition lowers seizure threshold perhaps through hyponatremia, or hypocalcemia [95, 96]. Traumatic brain injury may trigger seizures through GABA signaling disinhibition [97, 98]. Photosensitivity and altered circadian rhythms may lead to seizures through altered sensory integration [99, 100]. Other environmental triggers include various prenatal and postnatal factors [101], though these must be elucidated in further human studies.

Environmental and genetic factors possibly interact to trigger epilepsy [101]. Environmental stimuli may be required to express genes involved in epilepsy or enhance the effect of the susceptibility genotype [101]. This effect appears to differ between acquired and the so-called “genetic epilepsies”. Genetic events influence acquired epilepsies, and the genetic epilepsies are modified by acquired factors [102]. Given their epilepsies role, ion channels may be a mechanism involved in the gene-environment interaction [102]. Environmental and genetic factors may synergistically alter the density, stoichiometry, and post-translational modification of the same ion channels [102]. Acknowledging ecological factors and gene-environment interactions in future classification schemes will allow for greater representation of the aetiology and targeted management of people with epilepsy.

Future Epilepsy Classifications

Current classifications fulfill clinical needs through their applicability and adaptability in allowing certain epilepsies to be labelled as unknown. Dimensions that may improve the precision of discussions between and address various users of classification are lacking. Cross-contextual validation of the classification and emphasis on a team-based and individual-centred care are required to develop a comprehensive conceptualisation of care.

Validation of the Classification Cross-Contextually

Any classification scheme must be applicable to contexts differing in socioeconomic factors, cultures, and practice settings. This is the case in epilepsy as approximately 80% of people with epilepsy live in low-and-middle-income countries (LMICs) [103]. Three-fourths of them do not receive appropriate treatment [104, 105]. There is a dearth of epilepsy specialists in LMICs [104-106], so people receive care mainly through primary care, if any. They experience markedly higher premature mortality [107]. Hierarchies of importance placing epilepsy below other chronic conditions also contribute to a greater burden of epilepsy in LMICs.

Epilepsy classification is central in tackling the treatment gap and mortality burden in LMICs. Infectious diseases such as neurocysticercosis, malaria, and encephalitis are common in LMICs, and hence, valid case definitions linking these to epilepsies must be applied [108, 109]. Local variations in culturally-specific conceptualisations, manifestations, and epilepsy effects must be incorporated into classification schemes [110]. A study in rural China determined a substantial portion of generalised epilepsy previously characterised were labelled unknown upon the release of the 2017 ILAE-EC [35]. Forms of epilepsy common in LMICs differ from those in high income countries due to unique but often multiple risk factors [111]. Classification systems must be adaptable to different settings by all care providers to communicate effectively [104-106]. Clinicians must prioritise the needs of their population in...
classifying epilepsy to guide resource allocation [109]. ILAE has provided basic and advanced versions of classifications, but a singular classification scheme with flexibility to address local needs will enable public health efforts and policy [109]. It is also essential to allow classification with minimal or no use of technology [109]. Characteristics such as age of onset, semiology, family history, risk factors, treatment response, and relevant comorbidities can be assessed in clinics [109]. Even in LMICs, classifications should enable flexibility to identify locally relevant factors and resource constraints. These efforts can be coupled with capacity-building with field workers, increased availability of low-cost technology such as telemedicine, and public education campaigns to promote and provide appropriate treatment [112-115]. Ensuring broad applicability of the classification will include more people with epilepsy globally, thereby providing them with proper treatment and help close the treatment gap [104, 105].

**Comprehensive Team-Based Approach to Epilepsy**

A classification system must be coupled with a comprehensive team-based approach to care, research, and policymaking. Specialists create current classifications. Involving primary health care workers such as physicians, nurses, and ancillary staff, as well as researchers, policymakers, and other parties, into discussions will prove productive [116-118]. This will allow for appropriate refinement of specific terms used to describe seizures, create a glossary of key terms with associated definitions, and resolve discrepancies and ambiguities [11]. The classification system must then be clarified to all personnel to increase their understanding [119, 120].

Given the need for team-based approach, an elucidation of users’ needs of classification is warranted. Table 5 shows a list of potential users of an epilepsy classification and different levels of informational needs to accommodate all parties involved. Incorporating levels of descriptiveness into the classification will ensure that the communication-related needs of all individuals involved are met. The headline portion should be emphasised as the “lingua franca” among health-care personnel with varying experience, care centers, and across socio-cultural contexts [11]. A linkage to the previous classification systems to preserve continuity and allow for monitoring of trends is also necessary [119]. Professional organisations and educational bodies within existing health-care structures can have primary responsibility in encouraging adoption of the classification [121, 122].

**Person-Centered Care**

It is important to recognise the centrality of people with epilepsy in efforts to refine classifications. Any classification system must be explained to people and family members or caregivers and incorporate mechanisms to obtain feedback during development. This will increase understanding of the condition, connect with the care team through greater trust and self-involvement in care through acquiring additional information and engaging in self-advocacy [116-118, 120]. A classification system must involve consideration of person-centred outcomes and the needs of individuals in addition to traditional measures of disease status [123, 124]. Measures of health-related quality of life and personal impact should be acquired to assess how epilepsy or ASMs are impacting individuals [124]. This will guide clinicians regarding possible changes to the frequency of clinic visits, event monitoring or medication regimen or alert them of the need for referral to other physicians. Lastly, the classification scheme should emphasise a
holistic approach to care [125]. Epilepsy poses a large logistical and psychological burden to individuals [125-127]. Younger people may experience feelings of apprehension regarding revealing their diagnosis, while age-related metabolic changes often burden adults, cognitive decline, increased risk for seizure-related injuries, extensive comorbidities, and polypharmacy [125, 128]. Depression, anxiety, and a lack of social connection with other individuals are common [125, 128]. Provision of care appropriate to the specific concerns of people with epilepsy, psychosocial interventions to increase self-efficacy and locus of control, and measures to enhance social support will help empower people with epilepsy [126, 127].

**Technologies Likely to Impact Future Classifications**

Consideration of the effect of 7T magnetic resonance (MRI), next-generation sequencing (NGS), and artificial intelligence and machine learning on classification is required to reduce the fraction of unknown epilepsies and enhance the versatility of classification as future technological developments change clinical practice.

**7T MRI**

The 2017 ILAE classification scheme reclassified 27% of generalised and 7% of focal cryptogenic epilepsies into epilepsies of unknown type in one study [129]. There is a need to reduce the proportion of unknown epilepsies further. Seven Tesla MRI with its increased spatial resolution allowing visualisation of internal structures and differentiation of pathological tissue from normal tissue might conceivably help in reducing this proportion [130-133]. 7T provides for detection of lesions previously undiscovered [134-136]. Unaided review of 7T images reveals previously unseen lesions in 22% of cases, while utilising a morphometric analysis program raises this proportion to 43% [134]. 7T-morphometric analysis uncovers a quarter more lesions than 3T morphometrics [134].

Additionally, 7T allows characterisation of focal cortical dysplasia and hippocampal sclerosis and volumetric analysis of epilepsy-related brain regions [130, 131, 137-140]. The efficacy of 7T MRI in epilepsy classification relative to 3T MRI is yet to be fully assessed. Increased utilisation of 7T may allow precise classification by distinguishing epilepsy types and etiologies, thereby reducing the proportion of unknown epilepsies.

**Genome Sequencing**

NGS has markedly increased the speed of genome sequencing [141-143]. The ability of NGS to find causal mutations, including novel, and de novo mutations, associated with epilepsy syndromes enhances molecular diagnosis [144]. NGS is particularly useful to identify genetic causes in people with earlier seizure onset, and a family history [145, 146]. Currently available gene panels exhibit substantial variability, ascertaining up to 265 genes with reported diagnostic yields up to 48.5% [147]. NGS may be unable to determine the precise genetic etiology for epilepsies with polygenic inheritance [148] but its utility extends beyond genetic factors. NGS uncovers inherited metabolic disorders in 13% of people with normal metabolic investigations [149]. NGS has the potential to refine metabolic, infective, and autoimmune causes by identifying genetic alterations associated with these etiological categories. Similarly, NGS enhances understanding of pathogenesis through genotype-phenotype correlations, allowing for refined diagnosis [150]. Through inclusion of genes associated with epilepsy and the possibility
of discovering novel mutations, greater adoption of NGS may improve classification by comprehensively characterising genetic factors, catalysing reclassification of unknown epilepsies into well-delineated categories.

**Artificial Intelligence and Machine Learning**

The use of artificial intelligence and machine learning in epilepsy has grown substantially [151, 152]. Artificial neural networks have been utilised in tandem with multiwavelet transform techniques to diagnose epilepsy with high accuracy, sensitivity, and specificity based on EEG data [153-158]. Artificial intelligence and machine learning have also been used to localise seizure onset zones from EEG data [159-163]. For example, an unsupervised algorithm can collate the localisation of epileptiform discharges over a day into a single map [163]. Recording periods of less than two hours may enable clinically meaningful characterisation of seizure onset zone [161]. Recently, artificial intelligence and machine learning approaches have examined seizure classification [164-168]. A text mining approach based on ICD-9 yielded good performance in detecting complex focal seizure, simple focal seizure, and convulsive epilepsy based on data from the electronic medical record [165]. It is possible to distinguish temporal from extratemporal seizure by extracting spatiotemporal features from facial and pose semiology from EEG-records [166]. Studies analysing EEG data with multiple extraction methods have found high accuracy, sensitivity, and specificity [167, 168]. Development of capabilities to differentiate a greater number of seizure types, identify associated pathology and probable aetiology, and characterise epilepsies based on multimodal inputs may enable delineation of previously unrecognised factors to clarify ambiguities in classification, create additional classes, and reduce the proportion of unknowns.

**Conclusions**

Epilepsy classification is evolving with promising recent developments. Incorporation of stages of brain development, genetic and environmental triggers and changes in the demography into a modernised classification is necessary. Validation of this classification in different socioeconomic status contexts and coupling with a team-based approach and person-centred perspective is also required. These factors will ensure optimal care by addressing increasing the ease and precision of communication between the myriad of individuals who utilise the epilepsy classification. Technological advances including 7T MRI, genome sequencing, and artificial intelligence will refine the classifications further.
References
[1] Engel Jr J. ILAE classification of epilepsy syndromes. Epilepsy research 2006;70: 5-10.
[2] Falco-Walter JJ, Scheffer IE, Fisher RS. The new definition and classification of seizures and epilepsy. Epilepsy research 2018;139: 73-79.
[3] Zhang GQ, Sahoo SS, Lhatoo SD. From classification to epilepsy ontology and informatics. Epilepsia 2012;53: 28-32.
[4] Caveness W, AM LORENTZ HJM, RADERMECKER J. A proposed international classification of epileptic seizures. Epilepsia 1964;5: 297-306.
[5] Gastaut H. Clinical and electroencephalographical classification of epileptic seizures. Epilepsia 1970;11: 102-112.
[6] Fisher RS, Cross JH, French JA, Higurashi N, Hirsch E, Jansen FE, Lagae L, Moshé SL, Peltola J, Roulet Perez E. Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology. Epilepsia 2017;58: 522-530.
[7] Scheffer IE, Berkovic S, Capovilla G, Connolly MB, French J, Guilhoto L, Hirsch E, Jain S, Mathern GW, Moshé SL. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia 2017;58: 512-521.
[8] Engel Jr J. A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task Force on Classification and Terminology. Epilepsia 2001;42: 796-803.
[9] Lüders HO, Amina S, Baumgartner C, Benbadis S, Bermeo-Ovalle A, Devereaux M, Diehl B, Edwards J, Baca-Vaca GF, Hamer H. Modern technology calls for a modern approach to classification of epileptic seizures and the epilepsies. Epilepsia 2012;53: 405-411.
[10] Lüders H, Vaca GFB, Akamatsu N, Amina S, Arzimanoglou A, Baumgartner C, Benbadis SR, Bleasel A, Bermeo-Ovalle A, Bozorgi A. Classification of paroxysmal events and the four-dimensional epilepsy classification system. Epileptic Disorders 2019;21: 1-29.
[11] Rosenow F, Akamatsu N, Bast T, Bauer S, Baumgartner C, Benbadis S, Bermeo-Ovalle A, Beyenburg S, Bleasel A, Bozorgi A. Could the 2017 ILAE and the four-dimensional epilepsy classifications be merged to a new “Integrated Epilepsy Classification”? Seizure 2020.
[12] Scheffer IE. Epilepsy: A classification for all seasons? Epilepsia 2012;53: 6-9.
[13] Angeles D. Proposal for revised clinical and electroencephalographic classification of epileptic seizures. Epilepsia 1981;22: 489-501.
[14] Chang RS-k, Leung CYW, Ho CCA, Yung A. Classifications of seizures and epilepsies, where are we?—A brief historical review and update. Journal of the Formosan Medical Association 2017;116: 736-741.
[15] Dreifuss F, Martinez-Lage M, Johns RA. Proposal for classification of epilepsies and epileptic syndromes. Epilepsia 1985;26: 268-278.
[16] Classification Co, Epilepsy ToILA. Proposal for revised classification of epilepsies and epileptic syndromes. Epilepsia 1989;30: 389-399.
[17] Epidemiology Co, Prognosis ILAE. Guidelines for epidemiologic studies on epilepsy. Epilepsia 1993;34: 592-6.
[18] Engel Jr J. Report of the ILAE classification core group. Epilepsia 2006;47: 1558-1568.
[19] Berg AT, Berkovic SF, Brodie MJ, Bunchhalter J, Cross JH, van Emde Boas W, Engel J, French J, Glauser TA, Mathern GW. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005–2009. Epilepsia 2010;51: 676-685.
[20] Fisher RS, Cross JH, D'souza C, French JA, Haut SR, Higurashi N, Hirsch E, Jansen FE, Lagae L, Moshé SL. Instruction manual for the ILAE 2017 operational classification of seizure types. Epilepsia 2017;58: 531-542.

[21] Lüders HO, Burgess R, Noachtar S. Expanding the international classification of seizures to provide localization information. Neurology 1993;43: 1650-1650.

[22] Lüders H, Acharya J, Baumgartner C, Benbadis S, Bleasal A, Burgess R, Dinner D, Ebnner A, Foldvary N, Geller E. Semiological seizure classification. Epilepsia 1998;39: 1006-1013.

[23] Lüders H, Acharya J, Baumgartner C, Benbadis S, Bleasal A, Burgess R, Dinner D, Ebnner A, Foldvary N, Geller E. A new epileptic seizure classification based exclusively on ictal semiology. Acta neurologica Scandinavica 1999;99: 137-141.

[24] Loddenkemper T, Kellinghaus C, Wyllie E, Najm IM, Gupta A, Rosenow F, Lüders HO. A proposal for a five-dimensional patient-oriented epilepsy classification. Epileptic disorders 2005;7: 308-316.

[25] Lüders H, Amina S, Bailey C, Baumgartner C, Benbadis S, Bermeo A, Carreño M, Devereaux M, Diehl B, Eccher M. Proposal: different types of alteration and loss of consciousness in epilepsy. Epilepsia 2014;55: 1140-1144.

[26] Blumenfeld H, Meador KJ. Consciousness as a useful concept in epilepsy classification. Epilepsia 2014;55: 1145-1150.

[27] Ramantani G, Dümpelmann M, Koessler L, Brandt A, Cosandier-Rimélé D, Zentner J, Schulze-Bonhage A, Maillard LG. Simultaneous subdural and scalp EEG correlates of frontal lobe epileptic sources. Epilepsia 2014;55: 278-288.

[28] Bartolomei F, Cosandier-Rimele D, McGonigal A, Aubert S, Régis J, Gavaret M, Wendling F, Chauvel P. From mesial temporal lobe to temporoperisylvian seizures: a quantified study of temporal lobe seizure networks. Epilepsia 2010;51: 2147-2158.

[29] Manford M, Hart YM, Sander JW, Shorvon SD. The National General Practice Study of Epilepsy: the syndromic classification of the International League Against Epilepsy applied to epilepsy in a general population. Archives of neurology 1992;49: 801-808.

[30] Murthy J, Yangala R, Srinivas M. The syndromic classification of the International League Against Epilepsy: a hospital-based study from South India. Epilepsia 1998;39: 48-54.

[31] Oka E, Ohtsuka Y, Yoshinaga H, Murakami N, Kobayashi K, Ogino T. Prevalence of childhood epilepsy and distribution of epileptic syndromes: a population-based survey in Okayama, Japan. Epilepsia 2006;47: 626-630.

[32] Kellinghaus C, Loddenkemper T, Najm IM, Wyllie E, Lineweaver T, Nair DR, Lüders HO. Specific epileptic syndromes are rare even in tertiary epilepsy centers: a patient-oriented approach to epilepsy classification. Epilepsia 2004;45: 268-275.

[33] Olafsson E, Ludvigsson P, Hesdorffer D, Kjartansson O, Hauser WA, Gudmundsson G. Incidence of unprovoked seizures and epilepsy in Iceland and assessment of the epilepsy syndrome classification: a prospective study. The Lancet Neurology 2005;4: 627-634.

[34] Gao H, Sander JW, Xiao Y, Zhang Y, Zhou D. A comparison between the 1981 and 2017 International League Against Epilepsy classification of seizure types based on an outpatient setting. Epileptic Disorders 2018;20: 257-264.

[35] Wang F, Chen Z, Davagnanam I, Hoskote C, Ding D, Wang W, Yang B, Wang Y, Wang T, Li W. Comparing two classification schemes for seizures and epilepsy in rural China. European journal of neurology 2019;26: 422-427.
[36] Berg AT, Levy SR, Testa FM, Shinnar S. Classification of childhood epilepsy syndromes in newly diagnosed epilepsy: interrater agreement and reasons for disagreement. Epilepsia 1999;40: 439-444.
[37] Aicardi J. Syndromic classification in the management of childhood epilepsy. Journal of child neurology 1994;9: 2S14-2S18.
[38] Eriksson K, Koivikko M. Prevalence, classification, and severity of epilepsy and epileptic syndromes in children. Epilepsia 1997;38: 1275-1282.
[39] Keezer MR, Sisodiya SM, Sander JW. Comorbidities of epilepsy: current concepts and future perspectives. The Lancet Neurology 2016;15: 106-115.
[40] Ottman R, Lipton RB, Ettinger AB, Cramer JA, Reed ML, Morrison A, Wan GJ. Comorbidities of epilepsy: results from the Epilepsy Comorbidities and Health (EPIC) survey. Epilepsia 2011;52: 308-315.
[41] Tellez-Zenteno JF, Patten SB, Jetté N, Williams J, Wiebe S. Psychiatric comorbidity in epilepsy: a population-based analysis. Epilepsia 2007;48: 2336-2344.
[42] St. Germaine-Smith C, Liu M, Quan H, Wiebe S, Jette N. Development of an epilepsy-specific risk adjustment comorbidity index. Epilepsia 2011;52: 2161-2167.
[43] Gaitatzis A, Sisodiya SM, Sander JW. The somatic comorbidity of epilepsy: a weighty but often unrecognized burden. Epilepsia 2012;53: 1282-1293.
[44] Shlobin NA, Sander JW. Drivers for the comorbidity of type 2 diabetes mellitus and epilepsy: A scoping review. Epilepsy & Behavior 2020;106: 107043.
[45] Shlobin NA, Sander JW. Metabolic issues in people with epilepsy. Epilepsy & behavior: E&B 2020;108: 107081.
[46] Schenkel LC, Bragatti JA, Becker JA, Torres CM, Martin KC, de Souza AC, Manfro GG, Leistner-Segal S, Bianchin MM. Serotonin gene polymorphisms and psychiatry comorbidities in temporal lobe epilepsy. Epilepsy research 2012;99: 260-266.
[47] Noebels JL. Single-gene determinants of epilepsy comorbidity. Cold Spring Harbor perspectives in medicine 2015;5: a022756.
[48] Kramer U. Topical Review: Epilepsy in the First Year of Life: A Review. Journal of child neurology 1999;14: 485-489.
[49] Camfield P, Camfield C. Incidence, prevalence and aetiology of seizures and epilepsy in children. Epileptic Disorders 2015;17: 117-123.
[50] Fiest KM, Sauro KM, Wiebe S, Patten SB, Kwon C-S, Dykeman J, Pringsheim T, Lorenzetti DL, Jetté N. Prevalence and incidence of epilepsy: a systematic review and meta-analysis of international studies. Neurology 2017;88: 296-303.
[51] Tomson T, Xue H, Battino D. Major congenital malformations in children of women with epilepsy. Seizure 2015;28: 46-50.
[52] Samren E, Van Duijn C, Koch S, Hiilesmaa V, Klepel H, Bardy A, Mannagetta GB, Deichl A, Gaily E, Granström I. Maternal use of antiepileptic drugs and the risk of major congenital malformations: a joint European prospective study of human teratogenesis associated with maternal epilepsy. Epilepsia 1997;38: 981-990.
[53] Liu S, Yu W, Lü Y. The causes of new-onset epilepsy and seizures in the elderly. Neuropsychiatric disease and treatment 2016;12: 1425.
[54] Everitt AD, Sander JW. Incidence of epilepsy is now higher in elderly people than children. BMJ: British Medical Journal 1998;316: 780.
[55] Sander J, Cockerell O, Hart Y, Shorvon S. Is the incidence of epilepsy falling in the UK? The Lancet 1993;342: 874.
[56] Leppik IE, Birnbaum AK. Epilepsy in the elderly. Annals of the New York Academy of Sciences 2010;1184: 208.
[57] Shorvon SD. The causes of epilepsy: changing concepts of etiology of epilepsy over the past 150 years. Epilepsia 2011;52: 1033-1044.
[58] Cockerell OC, Johnson AL, Sander JW, Shorvon SD. Prognosis of epilepsy: a review and further analysis of the first nine years of the British National General Practice Study of Epilepsy, a prospective population-based study. Epilepsia 1997;38: 31-46.
[59] Kwan P, Schachter SC, Brodie MJ. Drug-resistant epilepsy. New England Journal of Medicine 2011;365: 919-926.
[60] Hao X, Goldberg D, Kelly K, Stephen L, Kwan P, Brodie MJ. Uncontrolled epilepsy is not necessarily the same as drug-resistant epilepsy: differences between populations with newly diagnosed epilepsy and chronic epilepsy. Epilepsy & Behavior 2013;29: 4-6.
[61] Sone D, Beheshti I, Maikusa N, Ota M, Kimura Y, Sato N, Koepp M, Matsuda H. Neuroimaging-based brain-age prediction in diverse forms of epilepsy: a signature of psychosis and beyond. Molecular psychiatry 2019: 1-10.
[62] Chen C-L, Shih Y-C, Liou H-H, Hsu Y-C, Lin F-H, Tseng W-YI. Premature white matter aging in patients with right mesial temporal lobe epilepsy: A machine learning approach based on diffusion MRI data. NeuroImage: Clinical 2019;24: 102033.
[63] Stefanatos GA, Kinsbourne M, Wasserstein J. Acquired epileptiform aphasia: a dimensional view of Landau-Kleffner syndrome and the relation to regressive autistic spectrum disorders. Child Neuropsychology 2002;8: 195-228.
[64] Hancock EC, Osborne JP, Edwards SW. Treatment of infantile spasms. Cochrane Database of Systematic Reviews 2013.
[65] Sander JW. The epidemiology of epilepsy revisited. Current opinion in neurology 2003;16: 165-170.
[66] Banerjee PN, Filippi D, Hauser WA. The descriptive epidemiology of epilepsy—a review. Epilepsy research 2009;85: 31-45.
[67] Källén K, Wyllie E, Lüders HO, Lachhwani D, Kotagal P. Hypomotor seizures in infants and children. Epilepsia 2002;43: 882-888.
[68] Fogarasi A, Tuxhorn I, Janszky J, Janszky I, Rásonyi G, Kelemen A, Halász P. Age-dependent seizure semiology in temporal lobe epilepsy. Epilepsia 2007;48: 1697-1702.
[69] Nordli DR. Varying seizure semiology according to age. In: Handbook of clinical neurology: Elsevier; 2013, p. 455-460.
[70] Noachtar S, Peters AS. Semiology of epileptic seizures: a critical review. Epilepsy & Behavior 2009;15: 2-9.
[71] Berg AT, Zelko FA, Levy SR, Testa FM. Age at onset of epilepsy, pharmacoresistance, and cognitive outcomes: a prospective cohort study. Neurology 2012;79: 1384-1391.
[72] Schmid R, Tandon P, Stafstrom CE, Holmes GL. Effects of neonatal seizures on subsequent seizure-induced brain injury. Neurology 1999;53: 1754-1754.
[73] Herrmann B, Seidenberg M, Bell B, Rutecki P, Sheth R, Ruggles K, Wendt G, O'Leary D, Magnotta V. The neurodevelopmental impact of childhood-onset temporal lobe epilepsy on brain structure and function. Epilepsia 2002;43: 1062-1071.
[74] Ferraro TN, Buono RJ. Polygenic epilepsy. Advances in neurology 2006;97: 389.
[75] Merwick A, O'Brien M, Delanty N. Complex single gene disorders and epilepsy. Epilepsia 2012;53: 81-91.
[76] Steinlein OK. Genetics and epilepsy. Dialogues in clinical neuroscience 2008;10: 29.
[77] Noebels J. Pathway-driven discovery of epilepsy genes. Nature neuroscience 2015;18: 344.
[78] Noebels JL. The biology of epilepsy genes. Annual review of neuroscience 2003;26: 599-625.
[79] Scheffer IE, Berkovic SF. The genetics of human epilepsy. Trends in pharmacological sciences 2003;24: 428-433.
[80] Jouveneau A, Eunson LH, Spauschus A, Ramesh V, Zuberi SM, Kullmann DM, Hanna MG. Human epilepsy associated with dysfunction of the brain P/Q-type calcium channel. The Lancet 2001;358: 801-807.
[81] Marini C, Guerrini R. The role of the nicotinic acetylcholine receptors in sleep-related epilepsy. Biochemical pharmacology 2007;74: 1308-1314.
[82] Chapman AG. Glutamate and epilepsy. The Journal of nutrition 2000;130: 1043S-1045S.
[83] Rogawski MA. AMPA receptors as a molecular target in epilepsy therapy. Acta Neurologica Scandinaivia 2013;127: 9-18.
[84] Bagdy G, Kecskemeti V, Riba P, Jakus R. Serotonin and epilepsy. Journal of neurochemistry 2007;100: 857-873.
[85] Ghasemi M, Schachter SC. The NMDA receptor complex as a therapeutic target in epilepsy: a review. Epilepsy & Behavior 2011;22: 617-640.
[86] Garcia C, Blair H, Seager M, Coulthard A, Tennant S, Buddles M, Curtis A, Goodship J. Identification of a mutation in synapsin I, a synaptic vesicle protein, in a family with epilepsy. Journal of medical genetics 2004;41: 183-186.
[87] Upreti C, Otero R, Partida C, Skinner F, Thakker R, Pacheco LF, Zhou Z-y, Maglakelidze G, Velišková J, Velišek L. Altered neurotransmitter release, vesicle recycling and presynaptic structure in the pilocarpine model of temporal lobe epilepsy. Brain 2012;135: 869-885.
[88] Wang VY, Chang EF, Barbaro NM. Focal cortical dysplasia: a review of pathological features, genetics, and surgical outcome. Neurosurgical focus 2006;20: 1-7.
[89] McTague A, Howell KB, Cross JH, Kurian MA, Scheffer IE. The genetic landscape of the epileptic encephalopathies of infancy and childhood. The Lancet Neurology 2016;15: 304-316.
[90] Scheffer IE, Wallace R, Mulley JC, Berkovic SF. Clinical and molecular genetics of myoclonic–astatic epilepsy and severe myoclonic epilepsy in infancy (Dravet syndrome). Brain and Development 2001;23: 732-735.
[91] Burgess R, Wang S, McTague A, Boysen KE, Yang X, Zeng Q, Myers KA, Rochtus A, Trivisano M, Gill D. The genetic landscape of epilepsy of infancy with migrating focal seizures. Annals of Neurology 2019;86: 821-831.
[92] Berg AT, Chakravorty S, Koh S, Grinspan ZM, Shellhaas RA, Saneto RP, Wirrell EC, Coryell J, Chu CJ, Mytinger JR. Why West? Comparisons of clinical, genetic and molecular features of infants with and without spasms. PloS one 2018;13: e0193599.
[93] Kramer U, Chi CS, Lin KL, Specchio N, Sahin M, Olson H, Nabbout R, Kluger G, Lin JJ, Van Baalen A. Febrile infection–related epilepsy syndrome (FURES): pathogenesis, treatment, and outcome: a multicenter study on 77 children. Epilepsia 2011;52: 1956-1965.
[94] Van Baalen A, Häusler M, Boor R, Rohr A, Sperner J, Kurlermann G, Panzer A, Stephani U, Kluger G. Febrile infection–related epilepsy syndrome (FURES): A nonencephalitic encephalopathy in childhood. Epilepsia 2010;51: 1323-1328.
Hackett R, Iype T. Malnutrition and childhood epilepsy in developing countries. Seizure 2001;10: 554-558.

Crepin S, Houinato D, Nawana B, Avode GD, Preux PM, Desport JC. Link between epilepsy and malnutrition in a rural area of Benin. Epilepsia 2007;48: 1926-1933.

Jennett B. Trauma as a cause of epilepsy in childhood. Developmental Medicine & Child Neurology 1973;15: 56-62.

Benardo LS. Prevention of epilepsy after head trauma: do we need new drugs or a new approach? Epilepsia 2003;44: 27-33.

Harding GF, Jeavons PM. Photosensitive epilepsy: Cambridge University Press; 1994.

Hofstra WA. The circadian rhythm and its interaction with human epilepsy: a review of literature. Sleep medicine reviews 2009;13: 413-420.

Ottman R, Annegers JF, Risch N, Hauser WA, Susser M. Relations of genetic and environmental factors in the etiology of epilepsy. Annals of neurology 1996;39: 442-449.

Berkovic SF, Mulley JC, Scheffer IE, Petrov S. Human epilepsies: interaction of genetic and acquired factors. Trends in neurosciences 2006;29: 391-397.

Ngugi AK, Bottomley C, Kleinschmidt I, Sander JW, Newton CR. Estimation of the burden of active and life-time epilepsy: a meta-analytic approach. Epilepsia 2010;51: 883-890.

Mbuba CK, Ngugi AK, Newton CR, Carter JA. The epilepsy treatment gap in developing countries: a systematic review of the magnitude, causes, and intervention strategies. Epilepsia 2008;49: 1491-1503.

Meyer A-C, Dua T, Ma J, Saxena S, Birbeck G. Global disparities in the epilepsy treatment gap: a systematic review. Bulletin of the World Health Organization 2010;88: 260-266.

Meinardi H, Scott R, Reis R, On Behalf Of The Ilae Commission on the Developing World JS. The treatment gap in epilepsy: the current situation and ways forward. Epilepsia 2001;42: 136-149.

Levira F, Thurman DJ, Sander JW, Hauser WA, Hesdorffer DC, Masanja H, Odermatt P, Logroscino G, Newton CR, Epilepsy ECotILA. Premature mortality of epilepsy in low-and middle-income countries: a systematic review from the Mortality Task Force of the International League Against Epilepsy. Epilepsia 2017;58: 6-16.

Newton CR, Garcia HH. Epilepsy in poor regions of the world. The Lancet 2012;380: 1193-1201.

Birbeck GL. Revising and refining the epilepsy classification system: Priorities from a developing world perspective. Epilepsia 2012;53: 18-21.

Kaddumukasa M, Kaddumukasa MN, Buwembo W, Munabi IG, Blixen C, Lhatoo S, Sewankambo N, Katabira E, Sajatovic M. Epilepsy misconceptions and stigma reduction interventions in sub-Saharan Africa, a systematic review. Epilepsy & Behavior 2018;85: 21-27.

Everitt AD, Sander J. Classification of the Epilepsies: Time for a Change? European neurology 1999;42: 1-10.

Van Hees VT, Van Diessen E, Sinke MR, Buitenhuis JW, Van Der Maas F, Ridder L, Otte WM. Reliable and automatic epilepsy classification with affordable, consumer-grade electroencephalography in rural sub-Saharan Africa. BioRxiv 2018: 324954.

Rajbhandari H, Joshi S, Malakar S, Paudel P, Jain P, Uppardaya K, Singh M, Patterson V. Epilepsy field workers, a smartphone application and telephone telemedicine: safe and effective epilepsy care in rural Nepal. Seizure 2019;64: 54-58.

Guekht A, Zharkinbekova N, Shpak A, Hauser WA. Epilepsy and treatment gap in urban and rural areas of the Southern Kazakhstan in adults. Epilepsy & Behavior 2017;67: 98-104.
[115] Hunter E, Rogathi J, Chigudu S, Jusabani A, Jackson M, Whittaker RG, Gray W, McNally RJ, Aris E, Mushi D. The epilepsy treatment gap in rural Tanzania: A community-based study in adults. Seizure 2016;36: 49-56.
[116] Hill CE, Thomas B, Sansalone K, Davis KA, Shea JA, Litt B, Dahodwala N. Improved availability and quality of care with epilepsy nurse practitioners. Neurology: Clinical Practice 2017;7: 109-117.
[117] Higgins A, Downes C, Varley J, Tyrell E, Normand C, Doherty CP, Begley C, Elliott N. Patients with epilepsy care experiences: comparison between services with and without an epilepsy specialist nurse. Epilepsy & Behavior 2018;85: 85-94.
[118] Fujimoto A, Ichikawa N, Sato K, Nishimura M, Enoki H, Okanishi T. Inclusion of general physicians in the multidisciplinary treatment team for epilepsy may lead to an economic benefit. Epilepsy & Behavior 2019;95: 56-60.
[119] Beghi E, Sander JW. The ILAE classification of seizures and epilepsies: implications for the clinic. Expert review of neurotherapeutics 2018;18: 179-183.
[120] Higgins A, Downes C, Varley J, Doherty CP, Begley C, Elliott N. Supporting and empowering people with epilepsy: Contribution of the Epilepsy Specialist Nurses (SEnSE study). Seizure 2019;71: 42-49.
[121] Noordegraaf M. Remaking professionals? How associations and professional education connect professionalism and organizations. Current Sociology 2011;59: 465-488.
[122] Fleishon HB, Itri JN, Boland GW, Duszak Jr R. Academic medical centers and community hospitals integration: trends and strategies. Journal of the American College of Radiology 2017;14: 45-51.
[123] Miller WR. Patient-centered outcomes in older adults with epilepsy. Seizure 2014;23: 592-597.
[124] Choi H, Hamberger MJ, Munger Clary H, Loeb R, Onchiri FM, Baker G, Hauser WA, Wong JB. Seizure frequency and patient-centered outcome assessment in epilepsy. Epilepsia 2014;55: 1205-1212.
[125] Miller WR, Bakas T, Buelow JM. Problems, needs, and useful strategies in older adults self-managing epilepsy: Implications for patient education and future intervention programs. Epilepsy & Behavior 2014;31: 25-30.
[126] Charyton C, Elliott JO, Lu B, Moore JL. The impact of social support on health related quality of life in persons with epilepsy. Epilepsy & Behavior 2009;16: 640-645.
[127] Amir M, Roziner I, Knoll A, Neufeld MY. Self-efficacy and social support as mediators in the relation between disease severity and quality of life in patients with epilepsy. Epilepsia 1999;40: 216-224.
[128] Wilde M, Haslam C. Living with epilepsy: a qualitative study investigating the experiences of young people attending outpatients clinics in Leicester. Seizure 1996;5: 63-72.
[129] Legnani M, Bertinat A, Decima R, Demicheli E, Higgie JR, Preve F, Braga P, Bogacz A, Scaramelli A. Applicability and contribution of the new ILAE 2017 classification of epileptic seizures and epilepsies*. Epileptic Disorders 2019;21: 549-554.
[130] Breyer T, Wanke I, Maderwald S, Woermann FG, Kraff O, Theysohn JM, Ebner A, Forsting M, Ladd ME, Schlamann M. Imaging of patients with hippocampal sclerosis at 7 Tesla: initial results. Academic radiology 2010;17: 421-426.
[131] Zhang Y, Lv Y, You H, Dou W, Hou B, Shi L, Zuo Z, Mao W, Feng F. Study of the hippocampal internal architecture in temporal lobe epilepsy using 7 T and 3 T MRI. Seizure 2019;71: 116-123.
[132] Thapaliya K, Urriola J, Barth M, Reutens DC, Bollmann S, Vegh V. 7T GRE-MRI signal compartments are sensitive to dysplastic tissue in focal epilepsy. Magnetic resonance imaging 2019;61:1-8.
[133] Sidhu MK, Duncan JS, Sander JW. Neuroimaging in epilepsy. Current opinion in neurology 2018;31:371-378.
[134] Wang J, Oh S, Blümcke I, Coras R, Krishnan B, Kim S, McBride A, Grinenko O, Lin Y, Overmyer M. Value of 7T MRI and post-processing in patients with nonlesional 3T MRI undergoing epilepsy presurgical evaluation. Epilepsia 2020.
[135] Colon A, van Osch M, Buijs M, Grond J, Hillebrand A, Schijns O, Wagner G, Ossenblok P, Hofman P, Buchem M. MEG-guided analysis of 7T-MRI in patients with epilepsy. Seizure 2018;60:29-38.
[136] Feldman RE, Delman BN, Pawha PS, Dyvorne H, Rutland JW, Yoo J, Fields MC, Marcuse LV, Balchandani P. 7T MRI in epilepsy patients with previously normal clinical MRI exams compared against healthy controls. Plos one 2019;14:e0213642.
[137] Shah P, Bassett DS, Wisse LE, Detre JA, Stein JM, Yushkevich PA, Shinohara RT, Elliott MA, Das SR, Davis KA. Structural and functional asymmetry of medial temporal subregions in unilateral temporal lobe epilepsy: A 7T MRI study. Human brain mapping 2019;40:2390-2398.
[138] Santyr BG, Goubran M, Lau JC, Kwan BY, Salehi F, Lee DH, Mirsattari SM, Burmeo JG, Steven DA, Parrent AG. Investigation of hippocampal substructures in focal temporal lobe epilepsy with and without hippocampal sclerosis at 7T. Journal of Magnetic Resonance Imaging 2017;45:1359-1370.
[139] Voets NL, Hodgetts CJ, Sen A, Adcock JE, Emir U. Hippocampal MRS and subfield volumetry at 7T detects dysfunction not specific to seizure focus. Scientific reports 2017;7:1-14.
[140] Veersema TJ, van Eijsden P, Gosselaar PH, Hendrikse J, Zwanenburg JJ, Spliet WG, Aronica E, Braun KP, Ferrier CH. 7 tesla T2*-weighted MRI as a tool to improve detection of focal cortical dysplasia. Epileptic Disorders 2016;18:315-323.
[141] Margulies M, Egholm M, Altman WE, Attiya S, Bader JS, Bemben LA, Berka J, Braverman MS, Chen Y-J, Chen Z. Genome sequencing in microfabricated high-density picolitre reactors. Nature 2005;437:376-380.
[142] Shendure J, Porreca GJ, Reppas NB, Lin X, McCutcheon JP, Rosenbaum AM, Wang MD, Zhang K, Mitra RD, Church GM. Accurate multiplex polony sequencing of an evolved bacterial genome. Science 2005;309:1728-1732.
[143] Schuster SC. Next-generation sequencing transforms today's biology. Nature methods 2008;5:16-18.
[144] Dunn P, Albury CL, Maksemous N, Benton MC, Sutherland HG, Smith RA, Haupt LM, Griffiths LR. Next generation sequencing methods for diagnosis of epilepsy syndromes. Frontiers in Genetics 2018;9:20.
[145] Ortega-Moreno L, Giráldez BG, Soto-Insuga V, Losada-Del Pozo R, Rodrigo-Moreno M, Alarcón-Morcillo C, Sánchez-Martín G, Díaz-Gómez E, Guerrero-López R, Serratosa JM. Molecular diagnosis of patients with epilepsy and developmental delay using a customized panel of epilepsy genes. PLoS one 2017;12:e0188978.
[146] Lee J, Lee C, Ki CS, Lee J. Determining the best candidates for next-generation sequencing-based gene panel for evaluation of early-onset epilepsy. Molecular Genetics & Genomic Medicine 2020: e1376.
Mercimek-Mahmutoglu S, Patel J, Cordeiro D, Hewson S, Callen D, Donner EJ, Hahn CD, Kannu P, Kobayashi J, Minassian BA. Diagnostic yield of genetic testing in epileptic encephalopathy in childhood. Epilepsia 2015;56: 707-716.

Møller RS, Dahl HA, Helbig I. The contribution of next generation sequencing to epilepsy genetics. Expert review of molecular diagnostics 2015;15: 1531-1538.

Costain G, Cordeiro D, Matviychuk D, Mercimek-Andrews S. Clinical application of targeted next-generation sequencing panels and whole exome sequencing in childhood epilepsy. Neuroscience 2019;418: 291-310.

Zhou P, He N, Zhang JW, Lin ZJ, Wang J, Yan LM, Meng H, Tang B, Li BM, Liu XR. Novel mutations and phenotypes of epilepsy-associated genes in epileptic encephalopathies. Genes, Brain and Behavior 2018;17: e12456.

Abbasi B, Goldenholz DM. Machine learning applications in epilepsy. Epilepsia 2019;60: 2037-2047.

Si Y. Machine learning applications for electroencephalograph signals in epilepsy: a quick review. Acta Epileptologica 2020;2: 1-7.

Walczak S, Nowack WJ. An artificial neural network approach to diagnosing epilepsy using lateralized bursts of theta EEGs. Journal of medical systems 2001;25: 9-20.

Gómez-Gil P, Juárez-Guerra E, Alarcón-Aquino V, Ramirez-Cortés M, Rangel-Magdaleno J. Identification of epilepsy seizures using multi-resolution analysis and artificial neural networks. In: Recent Advances on Hybrid Approaches for Designing Intelligent Systems: Springer; 2014, p. 337-351.

Abbasi R, Esmaeilpour M. Selecting Statistical Characteristics of Brain Signals to Detect Epileptic Seizures using Discrete Wavelet Transform and Perceptron Neural Network. International Journal of Interactive Multimedia & Artificial Intelligence 2017;4.

Fergus P, Hignet D, Hussain A, Al-Jumeili D, Abdel-Aziz K. Automatic epileptic seizure detection using scalp EEG and advanced artificial intelligence techniques. BioMed research international 2015;2015.

Guo L, Rivero D, Pazos A. Epileptic seizure detection using multiwavelet transform based approximate entropy and artificial neural networks. Journal of neuroscience methods 2010;193: 156-163.

Kumar SP, Sriraam N, Benakop P, Jinaga B. Entropies based detection of epileptic seizures with artificial neural network classifiers. Expert Systems with Applications 2010;37: 3284-3291.

Elahian B, Yeasin M, Mudigoudar B, Wheless JW, Babajani-Feremi A. Identifying seizure onset zone from electrocorticographic recordings: a machine learning approach based on phase locking value. Seizure 2017;51: 35-42.

Murin Y, Kim J, Parvizi J, Goldsmith A. SozRank: A new approach for localizing the epileptic seizure onset zone. PLoS computational biology 2018;14: e1005953.

Varatharajah Y, Berry B, Cimbalkin J, Kremen V, Van Gompel J, Stead M, Brinkmann B, Iyer R, Worrell G. Integrating artificial intelligence with real-time intracranial EEG monitoring to automate interictal identification of seizure onset zones in focal epilepsy. Journal of neural engineering 2018;15: 046035.

Nissen IA, Stam CJ, van Straaten EC, Wottschel V, Reijnveld JC, Baayen JC, de Witt Hamer PC, Idema S, Velis DN, Hillebrand A. Localization of the epileptogenic zone using interictal MEG and machine learning in a large cohort of drug-resistant epilepsy patients. Frontiers in neurology 2018;9: 647.
[163] Baud MO, Kleen JK, Anumanchipalli GK, Hamilton LS, Tan Y-L, Knowlton R, Chang EF. Unsupervised learning of spatiotemporal interictal discharges in focal epilepsy. Neurosurgery 2018;83: 683-691.
[164] Kassahun Y, Perrone R, De Momi E, Berghöfer E, Tassi L, Canevini MP, Sprefico R, Ferrigno G, Kirchner F. Automatic classification of epilepsy types using ontology-based and genetics-based machine learning. Artificial intelligence in medicine 2014;61: 79-88.
[165] Pereira L, Rijo R, Silva C, Agostinho M. ICD9-based text mining approach to children epilepsy classification. Procedia Technology 2013;9: 1351-1360.
[166] Ahmedt-Aristizabal D, Nguyen K, Denman S, Sridharan S, Dionisio S, Fookes C. Deep motion analysis for epileptic seizure classification. In: 2018 40th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC): IEEE; 2018. p. 3578-3581.
[167] Sriraam N, Temel Y, Rao SV, Kubben PL. A convolutional neural network based framework for classification of seizure types. In: 2019 41st Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC): IEEE; 2019. p. 2547-2550.
[168] Saputro IRD, Maryati ND, Solihati SR, Wijayanto I, Hadiyoso S, Patmasari R. Seizure type classification on EEG signal using support vector machine. In: Journal of Physics: Conference Series: IOP Publishing; 2019. p. 012065.